Clinical effects of liraglutide on diabetes control in Japanese type 2 diabetes mellitus patients.

Autor: Kawata, Takehiro, Kanamori, Akira, Kubota, Akira, Maeda, Hajime, Amamiya, Hikaru, Takai, Masahiko, Kaneshige, Hideaki, Minagawa, Fuyuki, Iemitsu, Kotaro, Kaneshiro, Mizuki, Ishikawa, Masashi, Takeda, Hiroshi, Takuma, Tetsurou, Mokubo, Atsuko, Machimura, Hideo, Obana, Mitsuo, Miyakawa, Masaaki, Naka, Yoshikazu, Terauchi, Yasuo, Toyoda, Masao
Zdroj: Diabetology International; Jun2014, Vol. 5 Issue 2, p98-104, 7p
Abstrakt: Aims: Our goal was to evaluate liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, in monotherapy and combination therapy for Japanese type 2 diabetes patients. Materials and methods: Patients with type 2 diabetes (111 men, 83 women; mean age 57.6 ± 12.6 years) were treated with liraglutide and divided into liraglutide monotherapy ( n = 147 patients, group A) and liraglutide-sulfonylurea (SU) combination therapy ( n = 47, group B) groups. Changes in clinical parameters after liraglutide administration were evaluated. Results: In both groups, significant decreases in glycosylated hemoglobin (HbA1c) were seen after 12 (group A, 7.01 ± 1.38 vs. 7.72 ± 1.57 %, p < 0.01; group b, 7.83 ± 1.19 vs. 8.44 ± 1.47 %, p < 0.01) and 24 weeks (group A, 7.21 ± 1.45 vs. 7.72 ± 1.57 %, p < 0.01; group B, 7.79 ± 1.22 vs. 8.44 ± 1.47 %, p < 0.01). In group A, body weight decreased significantly from before administration (74.5 ± 19.2 kg) to 12 (73.0 ± 17.8 kg) and 24 (72.8 ± 17.6 kg) ( p < 0.01) weeks. In group B, body weight decreased significantly from before administration (71.4 ± 17.4 kg) to 12 weeks (70.9 ± 17.9 kg; p < 0.01). Low-density lipoprotein (LDL) cholesterol decreased significantly in group A from before administration (112.6 ± 34.2 mg/dl) to 12 (107.7 ± 35.0 mg/dl; p < 0.005) and 24 (106.3 ± 26.8 mg/dl; p < 0.05) weeks. In group B, LDL cholesterol decreased significantly from before administration (112.1 ± 24.7 mg/dl) to 12 weeks (99.7 ± 24.7 mg/dl; p < 0.05) only. In both groups, no significant differences in systolic and diastolic blood pressures were observed at 12 and 24 weeks compared with before administration. Adverse events after starting liraglutide occurred in 45 patients (23.2 %), 23 (11.9 %) discontinued treatment. Conclusions: Once-daily liraglutide was well tolerated as monotherapy or combination therapy with SU, demonstrating superior glycemic control with a low rate of hypoglycemia and weight loss. [ABSTRACT FROM AUTHOR]
Databáze: Complementary Index
Externí odkaz: